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Abstract
BACKGROUND: Recent advances in medical care have increased life expectancy and improved 
the quality of life for people with Down syndrome (DS). These advances are the result of both pre-
clinical and clinical research but much about DS is still poorly understood. In 2020, the NIH 
announced their plan to update their DS research plan and requested input from the scientific and 
advocacy community.
OBJECTIVE: The National Down Syndrome Society (NDSS) and the LuMind IDSC Foundation 
worked together with scientific and medical experts to develop recommendations for the NIH 
research plan.
METHODS: NDSS and LuMind IDSC assembled over 50 experts across multiple disciplines and 
organized them in eleven working groups focused on specific issues for people with DS.
RESULTS: This review article summarizes the research gaps and recommendations that have the 
potential to improve the health and quality of life for people with DS within the next decade.
CONCLUSIONS: This review highlights many of the scientific gaps that exist in DS research. 
Based on these gaps, a multidisciplinary group of DS experts has made recommendations to 
advance DS research. This paper may also aid policymakers and the DS community to build a 
comprehensive national DS research strategy.
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1. Introduction
Down syndrome (DS) is the most common chromosomal disorder in humans, affecting 
about one of every 675 births [1]. Underlying the diverse spectrum of phenotypes seen in 
people with DS is an extra copy of chromosome 21 (Chr21), or trisomy 21 (T21), which 
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results in overexpression of many genes and changes in the proteome [2]. It is associated 
with intellectual disability, facial dysmorphism, short stature, and poor muscle tone or loose 
joints. There is also an increased risk of Alzheimer’s disease (AD), childhood leukemia, 
congenital heart disease, sleep dysfunction, metabolic disorders, autoimmune disorders such 
as thyroid disease, Type 1 diabetes, celiac disease, rheumatoid arthritis, and developmental 
disorders such as autism spectrum disorder (ASD) [3]. At the same time, however, 
individuals with DS have a decreased risk of developing atherosclerosis and certain adult 
cancers [4, 5]. With improved healthcare, people with DS are now living longer, with a life 
expectancy of > 55 years of age compared to just 25 years of age in the 1980’s. It is 
estimated that there are 210,000 people with DS in the United States and 40% are over the 
age of 30 years old [6].
Research to better understand DS across clinical, pathological, genetic, cellular, and 
molecular domains is essential to develop appropriate interventions to promote health and 
wellness across the lifespan. Such research has flourished in recent years, driven by 
technological innovations, emerging international collaborations, increased funding, and 
worldwide advocacy efforts. With the hope of leveraging the growing momentum to support 
DS research, two major DS organization, the National Down Syndrome Society (NDSS) and 
the LuMind IDSC Foundation crafted recommendations for a research strategy focused on 
the quality of life and care priorities of people with DS by 2030. The impetus for this effort 
was the US National Institutes of Health (NIH) RFI (Request for Information, Notice 
Number: NOT-HD-20–013) to update NIH research plans on Down syndrome in 2020. The 
NDSS and LuMind IDSC worked together with the scientific community to develop 
recommendations for the NIH. In addition, other DS organizations contributed, including the 
Jérôme Lejeune Foundation and the National Task Group on Intellectual Disabilities and 
Dementia Practices.
2. Methods
DS research is broad in scope and engages a wide spectrum of scientific and health care 
disciplines. To accomplish the goals of the project, eleven working groups made up of 
experts across multiple disciplines were established to focus on specific issues of special 
concern to people with DS. These topical groups addressed cognitive development; autism 
spectrum and behavioral disorders; impaired speech, language, hearing, and vision; heart 
and vascular disorders; sleep and respiratory problems; obesity, metabolic and 
musculoskeletal problems; cancer; immune system disorders; dental and oral health; and AD 
and aging. The eleventh working group focused on the importance of community 
engagement in all aspects of DS research to ensure that the strategy developed through this 
process is driven by and resonates with the DS community. Members of the community 
engagement working group came from a variety of organizations including LuMind IDSC, 
NDSS, local Down syndrome affiliates, and GiGi’s Playhouse. Important contributions were 
also made by caregivers and self-advocates to ensure that the DS community had input into 
the recommendations.
Workgroup members met via teleconference for over four months to discuss the state of the 
science in their respective topic areas, with plans to distill their findings into a research 
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agenda for the next decade. In April 2020, a two-day meeting was held in a virtual format 
due to the COVID-19 pandemic. The virtual meeting stimulated discussion that enabled top 
researchers in the field to share information, look for areas of overlap across workgroup 
topics, and identify unaddressed needs and research gaps. This paper summarizes areas of 
medical need for people with DS that have been understudied, unfunded or underfunded 
historically by federal and state agencies and foundations. The article is intended to serve as 
a call to action to the entire biomedical research community, to act as a catalyst for advocacy 
in research on DS, and to give research on DS the attention and funding that people with DS 
deserve.
3. Cognitive development and independence
To understand the effects of T21 on the development and function of the brain, three main 
questions were identified as areas to prioritize: 1) What brain regions and cell types are 
affected and what is the relationship of these effects to cognitive phenotypes? 2) When do 
deficits arise; are they the consequence of neurodevelopmental changes or functional 
changes in neural cells; and are they preventable or potentially correctable? 3) What are the 
underlying mechanisms by which T21 causes cognitive deficits? By understanding the 
answers to these questions at cellular and molecular levels, it may be possible to identify 
therapeutic targets and at what point targeting them might prove useful to positively affect 
cognition.
Human studies provide information about how brain anatomy and structure change across 
the lifespan and are also critical for genomic analyses. Anatomical studies indicate that DS 
is associated with a smaller cortex and cerebellum, with reductions in the number of neurons 
but increases in numbers of glia [7–9]. Neurons have dendritic spine defects and altered 
synaptic plasticity while glial defects indicate altered myelination [10, 11].
Deficits have also been reported in the function of synapses, mitochondria, and endosomes; 
and cell stress pathways appear to be activated. Several human Chr21 (HSA21) genes have 
been implicated in development, including some that regulate neural development and 
developmental signaling pathways and others involved in multiple stress mechanisms. Many 
more HSA21 genes have not been well studied and gene interaction effects must also be 
considered. In addition, T21 affects the expression of genes throughout the genome and so 
consideration of molecular and cellular pathways, metabolic and immune defects, and 
environmental factors may also impact brain function in DS.
Translating these anatomical and neural findings has helped refine what aspects of cognition 
are targeted in studies of individuals with Down syndrome. Specific constructs of executive 
functioning, learning and memory, and working memory are being targeted with an 
emphasis on determining the best measures for assessing these constructs and change in 
these constructs [12–16]. Further attention to the measurement of cognitive constructs has 
focused on social cognition, emotion recognition, and evaluating cognitive batteries [17–28]. 
The downstream impact of these cognitive constructs on functional outcomes has primarily 
considered children with DS, understanding the impact on formal education, and adaptive 
daily living skills [29–35]. Given a pattern of findings linking cognitive skills to fine and 
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gross motor control [36–41], preliminary small pilot trials to improve cognitive outcomes 
have more recently focused on the impact of physical activity interventions [42–44]. Both 
behavioral and pharmaceutical interventions are also being piloted to improve cognitive 
outcomes in individuals with DS [44–51]. Research on individuals with DS has frequently 
focused on between-group differences in comparison to other individuals with intellectual 
disability [52–57]. This focus has helped identify the unique cognitive phenotype common 
in individuals with DS. Group differences have also elucidated the impact of comorbid 
medical conditions on cognitive outcomes for individuals with DS, specifically cognitive 
outcomes for children with DS with or without comorbid congenital heart defects, sleep 
challenges including obstructive sleep apnea (OSA), and autism spectrum disorder [58–75].
Cognition may have impacts on other aspects of life such as independence. For individuals 
with DS, the degree of intellectual disability is one possible factor that may restrict 
independence. Studies show that speech ability and training, and access to a medical home 
can improve independence for individuals with DS [76, 77]. Measures of adaptive skills and 
surveys show that independence decreases with age in DS, which is likely multifactorial and 
presumably related to increasing risk for dementia [78, 79]. Drawing from studies of 
individuals with intellectual disability, speech independence, autonomy, and self-
management predict independence, while low physical fitness and changes in ADLs may 
indicate decreasing independence [80–82]. Importantly, independence for individuals with 
intellectual disability can be promoted through interventions including video prompts, video 
self-modeling, staff training, and the use of technology and remote support services [81, 83–
85].
While studies in humans are the gold standard, two types of research models are valuable to 
address cellular and molecular aspects of T21 in the brain: trisomic mouse models, and 
human T21 induced pluripotent stem cells (iPSCs) [86]. Human stem cell research enables 
investigations of T21 in the human genetic background at the molecular and cellular levels 
and enables mechanistic investigation. Current understanding of DS neurobiology is derived 
largely from mouse studies (e.g. Ts65Dn, Tc1) [87, 88]. Support for new mouse models that 
will minimize non-HSA21 genetic changes are needed [89]. In addition, it is becoming clear 
that aspects of gene regulation and brain development and function differ between mice and 
humans, so integrating information from these complementary models is essential to 
understand trisomy neurobiology and development [90–92].
Many drug candidates tested are reported to improve learning and memory in DS mouse 
models; however, the relevance of these findings to humans remains uncertain. Human cell 
and organoid models may be useful for testing drugs that target cell-based pathologies. 
Biomarkers – including functional measures such as functional magnetic resonance imaging 
(fMRI), electroencephalography (EEG), and functional near-infrared spectroscopy (fNIRS) - 
are clearly needed to advance drug development.
4. Cognitive development and independence research gaps
To gain a better understanding of cognitive deficits associated with DS, new preclinical 
models of cognition are needed to help establish the stage of cognitive development that 
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could be amenable to improvement. Therefore, inducible models of trisomy silencing or 
specific gene silencing should be developed. In addition, mouse studies are needed that can 
establish a correlation between changes in synaptic plasticity with learning and memory 
deficits. Finally, new DS models should reflect human physiology and genetic heterogeneity 
(e.g. outbred backgrounds).
More support of human cognition research in DS is also needed. To establish the link 
between cognitive performance and underlying brain structure, neurocognitive tools such as 
fMRI, EEG, and transcranial magnetic stimulation (TMS) should be utilized. Reliable and 
valid clinical outcome measures across the lifespan should be developed, as well as studies 
on the natural development of these associated constructs, to enable longitudinal studies and 
to advance clinical trials [12, 15]. It is important to support research focused on the wide 
heterogeneity of cognitive function across the DS population, including the effects of 
medical conditions (e.g. Attention-Deficit Hyperactivity Disorder (ADHD), ASD, anxiety, 
Acute Myelocytic Leukemia (AML), Acute Lymphocytic Leukemia (ALL)) in order to 
identify those individuals who will benefit from a particular intervention and who would be 
appropriate for inclusion in a clinical trial. To better understand all the factors that impact 
cognitive skills and meaningful functional outcomes, it is important to establish strong 
collaboration across behavioral disciplines.
There is need to include assessments of independence when studying human cognition. To 
understand the factors that contribute most to independence, additional research on the 
natural history of independence in people with DS is needed. Specifically, consideration 
should be given to what aspects are most meaningful to an individual with DS and 
caregivers, how to measure independence reliably and validly, and how to modify those 
factors. Successful interventions used in individuals with ID can guide implementation and 
study in individuals with DS. Large, multi-site, longitudinal studies could evaluate human 
cognition and independence simultaneously to connect the lessons learned from basic 
science to clinical significance; with the ultimate goal of improving independence.
5. Behavior and autism spectrum disorder
The prevalence of coexisting psychiatric or serious maladaptive behaviors in children and 
adolescents with DS is high and the consequences on education, family functioning, and 
socialization substantial. It has been reported that coexisting neurobehavioral and psychiatric 
disorders in those with DS range from 18 to 38% [93]. In a Swedish population-based study 
of children and adolescents with DS, 42% were diagnosed with ASD and 34% with ADHD 
[94], with the severity of ASD but not ADHD positively associated with the level of 
intellectual disability [95]. Other studies have found similar rates of ASD and behavioral 
symptoms in children with DS [96].
Some adolescents and young adults with DS also present with progressive and sometimes 
rapid cognitive deterioration or regression, which may dramatically impair independence 
and autonomy [97, 98]. A minority of individuals with DS experience worsening autistic 
characteristics that progress to a dementia-like state in what has been called Down syndrome 
disintegrative disorder (DSDD) [99, 100]. The causes of regression and DSDD remain 
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unclear, but may be associated with depression, hypothyroidism, autoimmune disorders, 
OSA, and/or subclinical epilepsy. One small study, which hypothesized an immune-related 
etiology, demonstrated significant improvements following treatment with immunotherapy 
[101].
6. Gaps in behavior and ASD research
Population-based normative data on maladaptive behaviors and psychiatric syndromes 
across the lifespan in DS are needed from studies with large and diverse cohorts. In addition, 
population-based studies are needed to evaluate the associations between ADHD, ASD, 
anxiety, depression, movement disorders, seizure disorders, and sleep disturbances. People 
with DS should be included in clinical trials of emerging therapies (e.g. novel biologics, 
anti-immune, anti-inflammatory, GABA/glutamate, and cell-based therapies) for autism and 
behavioral disorders. However, validated diagnostic and outcome measures need to be 
developed in order to assess behavioral disorders and autism for the DS population. In 
addition, neuroimaging and neurophysiology studies of behavioral disorders and ASD 
should be conducted in people with DS. Finally, there is a shortage of trained providers and 
researchers knowledgeable about DS. This has had a negative impact on advancing 
understanding of behavioral and psychiatric disorders in DS. Additional support for training 
fellowships in DS is needed.
7. Communication, vision, and hearing
A variety of structural and functional vision, hearing, and communication deficits are 
associated with DS, as well as other anomalies of the auditory/vestibular system. Variation 
in these structures and functions can be influenced by other aspects of the behavioral 
phenotype associated with DS. Taken together, these problems can interfere with the 
development and maintenance of communication skills critical to reading and oral language.
7.1. Communication disorders in DS
Difficulties with communication often occur in individuals with intellectual disability, but 
people with DS are 2.6 times more likely to have moderate communication difficulties and 
1.9 times more likely to have severe communication difficulties than people with intellectual 
disability not associated with this syndrome [102]. It is important to understand the reasons 
why many individuals with DS have lifelong problems with oral and written communication. 
Individuals with DS often exhibit delays in language development, with greater delays in 
expressive than receptive language [103]. Difficulties with language development are 
demonstrated from very early in development and continue into adulthood, with delays 
observed in the earliest stages of prelinguistic communication. These delays continue into 
the adolescent and young adult years, including the use of complex language for 
participation and social interaction in everyday life [104]. Speech is the main form of 
communication in 97% of all people with DS and therefore is critical to social interactions 
of all kinds. Reduced speech intelligibility is common in children and adults with DS [105, 
106], resulting from a combination of motor impairments, phonological delay or disorder, 
hearing loss, and craniofacial and laryngeal dysmorphology [107]. Speech intelligibility and 
language delays are major concerns for children with DS and their families. But many adults 
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with DS also experience lifelong difficulty with the intelligibility of their speech [108]. 
Nonetheless, children with DS do demonstrate gains in language development and a pattern 
of relative strengths and weaknesses in this domain, including more substantial delays in 
expressive syntax than in expressive vocabulary, for example [109]. Recent studies have also 
shown that verb usage is particularly limited in people with DS, leading to less language 
complexity and poorer discourse skills [110]. However, there are developmental changes in 
this profile over time [103, 104, 111]. For example, receptive and expressive vocabulary 
have been shown to improve during early adolescence but to decline in late adolescence and 
early adulthood, perhaps foreshadowing the later more dramatic declines associated with 
early onset Alzheimer’s disease. Given nuances in language for people with DS, treatment 
and intervention for language impairments in this population must consider both the 
language phenotype and overall behavioral phenotype [103, 104, 112], leveraging language 
strengths to support treatment and intervention efforts.
7.2. Gaps in communication research
Research focused on the development of assessments and new interventions for improved 
communication for individuals with DS across the lifespan is needed. Validated, 
standardized measures of language may be used but may need modification for extensive 
testing in the DS population. The development of DS-specific language norms is needed, 
with the incorporation of other psychometric features, especially those relevant for use as 
outcome measures in treatment studies, including clinical trials. Studies that can distinguish 
the effects of motor speech disorders from effects caused by anatomical dysmorphology are 
needed to develop tools for clinical assessments and to facilitate the development of effective 
interventions across the lifespan. More and larger studies assessing the efficacy of high-
intensity speech interventions in young children are needed. There is also a need to more 
fully understand the ways in which the social and linguistic environment supports or hinders 
language development in order to identify potential pathways and mechanisms for 
intervention. Lastly, there is a need for studies on language and communication in adulthood 
to understand the trajectory of improvement and possible age-related decline.
7.3. Vision disorders in DS
Ocular disorders are common in DS with reduced visual acuity observed even with 
refractive corrections. Specific impairments in vision include elevated refractive errors, 
strabismus, nystagmus, and corneal abnormalities all of which may contribute in part to the 
reduced visual acuity observed in DS [113]. These disorders are associated with abnormal 
visual developmental and possibly structural differences in the retina, cornea, and optic 
nerve [114–117]. Improved clinical strategies are needed to address visual deficits in this 
group, as most individuals do not achieve normal visual performance with standard 
refractions. Early intervention is likely to aid visual development for children with DS, but 
structural deficits in ocular tissues, such as those commonly observed in the cornea, may 
progressively worsen in later years, leading to additional losses in vision quality.
7.4. Gaps in vision research
A greater understanding is needed regarding the causes of reduced visual acuity, e.g., the 
contributions of retinal, corneal, and neural abnormalities. There is also a need to expand 
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studies of the impact of optimized refractive correction on visual outcomes to younger 
children. Longitudinal studies with cohorts large enough to achieve statically meaningful 
results are needed to understand the progression of structural changes in the ocular system 
and correlations with visual outcomes across the lifespan.
7.5. Hearing loss and vestibular problems in DS
Hearing loss is common in children and adults with DS. The incidence of hearing loss in 
neonates and infants with DS is between 15% and 30% [118, 119]; between 25% and 85% 
in children and adolescents [120, 121]; and between 50% and 75% in adults [122, 123]. 
While most hearing loss in DS is associated with otitis media with effusion, mixed 
conductive-sensorineural loss is also common and is usually secondary to inner ear 
malformations [124], which may also cause symptoms of vestibular dysfunction such as 
dizziness, vertigo, and balance disorders. Anomalies in the auditory system in DS have been 
reported for the outer ear, middle ear, and inner ear [125–131]. Other factors that may 
contribute to vestibular dysfunction in DS include: hypotonicity, joint laxity, decreased deep 
tendon reflexes and delays in reaction timing, and equilibrium reactions. The vestibular 
system works with other senses such as vision and proprioception to maintain balance and 
motor coordination.
7.6. Gaps in hearing loss and vestibular function research
More research on the detection and treatment of hearing loss across the lifespan of 
individuals with DS is needed. Assessment and detection measures are needed that account 
for developmental and aging effects as well as structural differences that may be present. 
Research on strategies to increase the use of hearing aids among adults with DS who has 
hearing loss also is needed. There is evidence that DS-AD is sometimes misdiagnosed since 
the symptoms observed may actually be due to hearing impairment or other sensory deficits 
[132]. Hearing loss may also be a contributing factor given that it is more frequent among 
adults with DS and co-morbid dementia [133]. More research on the diagnosis of hearing 
impairment in adults with DS is needed.
8. Heart and vascular
Congenital heart disease (CHD) represents one of the cardinal features of DS, affecting more 
than 40 percent of infants with T21 [134]. Multiple subtypes are seen, including complete 
atrioventricular septal defects (AVSD), ventricular septal defect, atrial septal defect, partial 
atrioventricular septal defect, Tetralogy of Fallot, and patent ductus arteriosus; and the 
presence of multiple anomalies is common [135–139]. Early diagnosis improved surgical 
outcomes, and better perioperative care have resulted in significant increases in survival over 
the past two decades, contributing to the improved longevity for people with DS.
Trisomy 21 clearly significantly increases the risk for AVSD and other heart defects but is 
not sufficient to cause CHD. It was originally hypothesized that T21 unmasks a common 
susceptibility variant that explained the hugely increased in risk for AVSD observed in DS. 
Using a genome-wide association study approach, no evidence for this hypothesis was 
obtained [140–142]. Instead, current findings suggest an increased burden of rare variants as 
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contributing to risk for AVSD in DS, some of which overlap with those found for non-
syndromic CHD (nsCHD). Such variants (including single-nucleotide variants, microRNAs, 
and copy number variants) are not restricted to chromosome 21, but found throughout the 
genome [140, 141, 143–145]. Thus, the modified hypothesis states that having an extra 
Chr21 predisposes to abnormal heart development, but additional rare variants or 
environmental triggers are required to exceed a susceptibilty threshold to lead to CHD. 
Support for this hypothesis and proof-of-principle has been provided by the Ts65Dn mouse 
model [146, 147]. Evidence for altered pathways include the ciliome, Notch signaling, 
VEGF-A and folate/homocysteine metabolism [144, 145, 148].
In addition to CHD, individuals with DS often experience other cardiovascular problems 
including cardiac arrhythmia, pulmonary hypertension, and sleep apnea. A higher risk of 
cerebrovascular events including stroke and transient ischemic attack is also seen, 
particularly in women [149]. Immune dysfunction and thyroid dysfunction – both prominent 
in DS –may also affect cardiovascular function; and extra-cardiac comorbidities such as 
differences in vascular resistance and arterial stiffness may contribute to cardiovascular 
dysfunction. Alterations in heart rate variability and blood pressure in the low normal range 
are also relatively common in DS and may reflect autonomic dysfunction [150]. The 
consequences of lower blood pressure and heart rate in DS over the lifespan are poorly 
understood, as is the effect of exercise on autonomic function. The Ts65Dn mouse model 
also demonstrates reduced blood pressure and heart rate variability alterations from wild-
type mice, suggesting this model could be used to explore mechanistic changes in 
cardiovascular function across the lifespan in DS [151]. Moyamoya disease may also occur 
in people with DS [152] and contributes to increased stroke risk over the lifespan, 
particularly with those who have blood pressure in a higher, but normal range [153].
9. Heart and vascular disease research gaps
The genetic factors and dysregulated pathways in DS-associated CHD are just beginning to 
be identified. The roles of nuclear and mitochondrial genes and their possible interactions 
with HSA21 genes have yet to be determined. Research integrating transcriptomic, 
metabolomic, proteomic and other -omic approaches should be applied to these knowledge 
gaps. In addition, epigenomic approaches could facilitate identification of environmental 
exposures associated with CHD. The integration of -omics data could help identify 
underlying molecular mechanisms, help define genotypes and phenotypes which could lead 
to prevention and novel treatments. From the clinical and epidemiological research 
perspective, larger sample cohorts with well-defined heart phenotypes (cardiac and extra-
cardiac) are needed to define genotype / phenotype correlations in DS-associated CHD. 
Complementing these studies with model systems is essential to understand genotype 
functions and their interactions with the environment.
More clinical research is needed to better understand cardiovascular disease in DS. For 
example, there is a need to advance understanding of the surgical and postoperative care 
needs of children with DS and CHD. The early detection of Moyamoya disease is essential 
for better outcomes but this will require a better understanding of early risk factors and the 
development of novel biomarkers. The role of lifestyle factors such as sedentary lifestyle and 
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exercise on cardiovascular function in individuals with DS is not well understood. There is 
early evidence that increasing exercise, even passive exercise, may also have positive effects 
on cognition and learning [44, 154]. One issue that needs to be addressed to advance clinical 
research in DS is the issue of control groups. Proper controls are essential for cardiovascular 
research in DS, however, there are many different types of controls utilized (heart rate 
controls, intellectual disability without DS controls, BMI controls, activity level controls), 
which complicates interpretation of data from these studies. The field should address this 
issue and build consensus around a single type of DS control.
10. Sleep and respiratory
Individuals with DS are prone to develop OSA due to a combination of anatomic and 
neuromotor factors, such as midfacial hypoplasia, macroglossia, tracheal and laryngeal 
abnormalities, and hypotonia [155, 156]. With aging, the prevalence of OSA increases but it 
remains frequently underdiagnosed. Untreated sleep disorders such as OSA may contribute 
to worse cognitive function and accelerate cognitive decline [45, 46, 47]. Other respiratory 
problems including increased risk of infection are common in children and adults with DS 
due to a combination of the mentioned anatomical and functional abnormalities, immune 
dysfunction, and cardiac problems [157, 158]. For example, respiratory syncytial virus 
(RSV) infection is particularly prevalent and associated with high morbidity and mortality in 
infants and children with DS [159]. Dysphagia, also common in DS, increases the risk of 
aspiration and recurrent pneumonia [160].
Children with DS also have an increased risk for developing multifactorial pulmonary 
hypertension [161] associated with hypoxemia, OSA, pulmonary hypoplasia, increased 
pulmonary vascular resistance, and increased hemodynamic stress. The sub-group of 
children with DS and CHD are at particularly high risk of developing pulmonary 
hypertension, but it can also be a consequence of respiratory distress syndrome [162]. Lower 
airway anomalies such as hypoplasia of the alveoli and other more distal structures have also 
been reported [163].
11. Gaps in sleep and respiratory research
Despite previous sleep research, normative data on sleep patterns in DS are still lacking. In 
children and adults with DS, research is needed to evaluate the association of a characteristic 
DS sleep phenotypes, i.e. reduced sleep efficiency, decreased rapid-eye movement (REM) 
sleep, and increased slow-wave sleep (SWS, also called non-rapid-eye-movement 3 
(NREM3 or N3) sleep), with learning and behavioral difficulties in the context of baseline 
neurocognitive impairment.
Neurocognitive studies to evaluate the impact of sleep disturbances in adults with DS and its 
relationship to cognition, behavior, and quality of life are needed. Indeed, it is important to 
prospectively assess the impact of sleep disturbances on cognitive impairment and 
progression to dementia in adults with DS. Objective sleep evaluation methods and a DS-
specific cognitive battery are needed to properly evaluate baseline relationships and 
intervention outcomes. More research is required on circadian rhythm disruptions in people 
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with DS. Finally, the design and validation of new sleep questionnaires and simple at-home 
devices to screen for sleep disorders are needed.
Pulmonary hypertension is a significant cause of morbidity in children and infants with DS. 
More research is needed to distinguish the clinical and molecular pulmonary hypertension 
phenotypes in DS compared to children without DS. In addition, non-invasive airway 
evaluation guidelines for children with DS that incorporate multidisciplinary aerodigestive 
programs are needed.
12. Musculoskeletal, metabolic factors, and obesity
Past research findings indicate that individuals with DS across the lifespan are at high risk 
for musculoskeletal issues and metabolic disorders such as obesity and Type 2 diabetes [164, 
165]. The genetic and molecular mechanisms that underlie musculoskeletal and metabolic 
dysfunction in DS remain unclear. T21 has been associated with altered insulin secretion, 
impaired hepatic glucose metabolism, and altered insulin sensitivity in muscle. Autonomic 
dysfunction with altered peripheral blood flow to muscle may affect blood distribution to the 
muscle and build-up of toxins, which may lower the pain threshold and tolerance for 
physical activity. Research in both humans with DS and DS mouse models has identified 
changes in metabolism related to obesity, inflammation, mitochondrial function, immunity, 
insulin resistance, and glucose tolerance [166].
Individuals with DS across the lifespan are at higher risk to be overweight and obese 
compared to the general population [167–170]. The possible determinants of increased 
weight and obesity in individuals with DS include low resting metabolic rate, low physical 
activity levels, and unhealthy dietary behaviors [168, 171–173]. Obesity appears to have 
adverse health outcomes among individuals with DS such as dyslipidemia, 
hyperinsulinemia, OSA, and gait problems [168, 174–178].
Musculoskeletal problems associated with DS include muscle hypotonia and joint laxity, 
both of which can cause ambulation difficulties and other functional impairments [164]. 
Moreover, these problems may contribute to reduced physical activity, increased levels of 
obesity [168], and an elevated risk of many disorders including heart disease, Type 2 
diabetes, cancer, and osteoporosis [179]. Individuals with DS across the lifespan have very 
low physical fitness and physical activity levels [180–184]; these attributes may be either 
causes or outcomes of musculoskeletal and metabolic issues or bidirectional relationships 
may be at play. Certainly, improving the physical activity and physical fitness levels of 
individuals with DS may positively impact their health and functional profiles.
There are ongoing international efforts to better understand metabolic dysregulation in DS. 
The Gene Overdosage and comorbidities during the early lifetime in Down syndrome (GO-
DS21) project recently launched in the European Union to explore metabolism and 
metabolomics in DS.
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13. Gaps in musculoskeletal and metabolic research
Longitudinal studies on muscle development and weight changes across the lifespan in DS 
are needed to explore differences between people with DS and the general population. These 
studies should evaluate the development of obesity across the lifespan, delineate its causes 
and clinical impact, and test interventions for reducing obesity in individuals with DS. 
Hypotonia is very common in DS but it is not well understood. Research on the genetic and 
biochemical basis of hypotonia including the role of mitochondrial alterations is needed to 
clarify the etiology of the condition. In addition, the effect of impaired autonomic function 
on cardiovascular fitness is not well understood and needs more research. There have been a 
few small physical activity intervention trials in DS [185–187]. More and larger trials are 
needed to test the effects of physical activity as an intervention on a range of health 
outcomes and the modifications that may be needed to implement such interventions in the 
DS population.
14. Cancer
Although there is no difference in the overall incidence of cancer among the DS population 
compared to the non-DS population, DS is associated with a decreased incidence of solid 
tumors and an increased incidence of hematological malignancies, specifically acute 
leukemias [5, 188].
Compared to the non-DS population, individuals with DS are 500 times more likely to be 
diagnosed with acute myeloid leukemia (ML-DS) and 20 times more likely to be diagnosed 
with acute lymphoblastic leukemia (DS-ALL). Survival outcomes for ML-DS are superior to 
the general population, with event-free survival rates ranging from 80–100%. Clinical trials 
are focused on optimizing chemotherapy to reduce toxicity while maintaining survival 
outcomes [189, 190]. Outcomes for patients with DS-ALL are inferior to the general 
population and patients with DS treated for ALL have excess treatment toxicity and 
treatment morbidity. Novel approaches to treat DS-ALL are needed to improve survival and 
decrease treatment morbidity [191, 192]. Factors that contribute to variability in treatment 
response and outcomes are not fully understood but may include differences in the genetics 
and biology of DS-leukemia as well as those related to the DS-phenotype (i.e., gene dose 
effect from T21).
The risk for DS-leukemia (ML-DS and DS-ALL) is greatest during early childhood (ages 1–
4), a critical neurodevelopmental period. Treatment for DS-leukemia (DS-ALL in particular) 
involves central nervous system (CNS)-directed chemotherapy. Treatment for DS-ALL is 2.5 
– 3 years in duration with extended periods of immunocompromise resulting in missed 
opportunities for social interaction, early intervention and education services that support 
developmental gains throughout childhood. It has been well-established that survivors of 
childhood ALL without DS have a higher risk of neurocognitive deficits [193, 194]. Given 
the preexisting cognitive vulnerability in DS, the cumulative impact of CNS-directed 
treatment and missed community participation may add to neurocognitive deficits. 
Compared to survivors of leukemia without DS, survivors of DS-leukemia may be at 
increased risk for treatment late effects and poorer quality of life [195–197]. Improved 
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understanding of the impact of leukemia and its therapy on neurodevelopmental, health, and 
quality of life outcomes has the potential to inform modifications to treatment, approaches to 
supportive care during therapy, and interventions to ameliorate side effects.
15. Gaps in cancer
Improved characterization of clinical, biological, and genetic phenotype in DS-leukemia is 
needed to identify therapeutic targets and further refine treatment. A better understanding of 
DS-leukemia genomics may also have implications for surveillance and diagnosis. 
Evidence-based approaches to supportive care, improved assessment and management of 
side effects and toxicities in DS leukemia needs to be developed. Longitudinal studies of 
neurodevelopmental, health, and quality of life outcomes in cancer survivors beginning 
during therapy, in order to inform supportive care and interventions to ameliorate problems 
are also needed.
15.1. Immune system disorders
The architecture of the immune system is significantly altered in people with DS, with 
common findings of leukopenia, lower B cell frequencies, and pro-inflammatory shifts 
including increased proportion of memory T cells, pro-inflammatory T cell subsets, and pro-
inflammatory cytokine-producing cells [198, 199]. Consistent with this pro-inflammatory 
milieu, people with DS exhibit a highly increased risk of developing autoimmune diseases 
including thyroid disease, Type 1 diabetes, celiac disease, rheumatoid arthritis, systemic 
lupus erythematosus, and atopy. Paradoxically despite this augmented immune response, 
individuals with DS are more susceptible to infectious disease, which account for 50% of 
deaths in individuals with DS [3]. This includes increased mortality secondary to RSV and 
now to COVID-19 infections. [198–204]. Additionally, these diseases may manifest at 
earlier ages and greater severity in people with DS.
16. Gaps in immune system disorders research
Critical gaps exist in our understanding of the specific facets of immune dysregulation and 
the underlying mechanistic pathways, which drive predisposition to autoimmunity and poor 
outcomes with infection. Research is needed to clarify which existing therapeutics are most 
effective for people with DS and to prioritize targets for novel therapeutics. Although 
candidate genes on Chr21, including IFNAR1/2 and DYRK1A, have been identified, the role 
of most HSA21 genes is unclear. Additionally, studies showing that T21 can impact 
transcription on other chromosomes suggests that the scope of this research will likely 
extend beyond Chr21. Because the risk of autoimmunity increases with age, longitudinal 
studies are also needed with genomic confirmation of full or partial trisomy of genes 
associated with immunity. Sampling prior to developing autoimmunity is necessary to allow 
us to better understand who is at higher risk, and how that risk might be mitigated. 
Genotyping for known autoimmunity-associated polymorphisms will help us better 
understand how T21 modulates single nucleotide polymorphisms (SNP)-associated risk. 
Similar SNPs on T21 that are normally rendered silent might exert their effect due to gene 
dosage, but also perhaps due to overall perturbed clinical state. Linked clinical metadata, 
particularly the severity of autoimmunity and response to specific therapeutics, will enhance 
Hendrix et al. Page 13













translational significance of this work. To better understand the role of thymic dysfunction in 
autoimmunity, studies should assess the consequences of thymectomy (e.g. on the 
differentiation of T cells into subsets and the production of self-reactive T cells) in children 
with CHD who undergo this procedure to provide surgical access as part of their cardiac 
surgery. As the immune system penetrates all organ systems, it is important to better 
understand how the immune system connects to dermatological, neurological, and 
gastrointestinal systems and how it may influence the course of disease in cancer and AD 
alike. Finally, the emergence of the COVID-19 pandemic makes research in the DS 
population a priority including for the development of potential therapies.
17. Dental & oral health
Issues with dental and oral health are very common in DS and often directly impact the 
quality of life. There are many differences between individuals with DS and the general 
population [205]. Differences include delayed eruption in babies and children, differences in 
eruption sequences for primary teeth, microdontia, and hypodontia [206, 207]. People with 
DS may have large tongues (macroglossia), or they may have an average size tongue but a 
small upper jaw that makes their tongue too large for their mouth (relative macroglossia) 
causing difficulties with speech and breathing and contributing to OSA. Small jaws and 
microdontia can cause tooth crowding and problems with spacing where the teeth of the 
upper and lower jaws do not touch affecting the bite. Orthodontics may be able to improve 
some of these issues, but this may present a particular challenge for children with DS. 
Finally, there are reports that people with DS have a lower risk for cavities; however, much 
of that research was done when people with DS lived in institutions and had very restricted 
diets. As such, more research is needed on the caries prevalence in people with DS [208, 
209].
People with DS may have an aggressive form of periodontitis characterized by rapid 
progression, significant bacterial and inflammatory burden, and an onset as early as 6 years 
of age, which could contribute to other systemic diseases as well [210–213]. However, 
studies have shown that periodontal therapies may be effective [214]. It has been observed 
that in elderly cognitively normal people, measures of periodontal destruction and 
periodontal dysbiosis is associated with brain amyloidosis [215]. Given the high prevalence 
of both AD and periodontal disease in DS, more research is needed to determine if 
periodontitis contributes to AD pathology [216].
Dental and oral health has a broad impact on overall health and quality of life. Thus, more 
research is needed to understand the impact of dental and oral health in DS and the 
association with development, sleep disorders, the immune system, and other common co-
occurring conditions. This research could lead to greater insights in the role of oral health on 
the overall health of people with DS and lead to better treatment options.
18. Dental and oral health research gaps
The development and validation of cellular and animal models are needed to better 
understand the characteristics of dental and oral health in individuals with DS. More 
Hendrix et al. Page 14













research is needed to better characterize the differences between DS and the general 
population in dental development and oral health to help inform medical guidelines. 
Furthermore, the impact of periodontal disease on the overall health of individuals with DS 
is not well understood. DS mouse models should be employed to study the possible 
association between periodontal disease and AD related pathology such as Aβ plaques, 
neurofibrillary tangles, and neurodegeneration. Longitudinal and interventional studies 
should evaluate the role of periodontal inflammation and bacterial dysbiosis on AD 
progression [217].
19. Alzheimer’s disease and aging
With improved care and extended longevity for people with DS, there has been an increase 
in age-related disorders, especially AD, which typically occurs at an earlier age than that 
observed in the general population [218] (Fig. 1). Indeed, compared to people without 
triplication of Chr21, individuals with DS are at a markedly increased risk of developing 
AD. By age 40 years, β-amyloid plaque pathology and neurofibrillary tangles are present in 
almost all people with full trisomy [219]. It is estimated that the lifetime risk of AD is > 
90% and that AD is the leading cause of death for adults with DS [220, 221]. However, few 
adults with DS associated AD (DS-AD) or with other age-related disorders receive 
appropriate care for a number of reasons. These include a shortfall of accepted and validated 
standards for care, lack of practitioners trained to provide support and evaluate people with 
DS-AD, inadequate data on the natural history of persons with DS-AD, lack of DS-specific 
diagnostic and treatment approaches, lack of evidence of efficacy of existing treatments, and 
inadequate resources for caregivers.
The reasons for the increased incidence of DS-AD are multifactorial but a primary driver is 
likely related to genes on HSA21. Among the genes expressed on HSA21 is the gene for 
amyloid precursor protein (APP). Overexpression of this protein due to trisomy leads to 
excess production of the toxic, AD associated protein, β-amyloid. β-amyloid accumulates 
within senile plaques in the brain but also can affect the blood vessels of the brain (cerebral 
amyloid angiopathy or CAA) [222]. Although most people with DS are rarely affected by 
atherosclerosis and arteriosclerosis, which are two risk factors for cerebrovascular pathology, 
there is significantly more CAA in DS than in people without DS or when compared to older 
people with AD [223, 224]. Neuroinflammation may also show unique signatures in the 
brains of people with DS, with features both common to and unique from sporadic AD 
[225]. Thus, there are multiple pathological events that occur either serially or in tandem to 
accelerate the development of AD in people with DS.
Genetic, cell biology, cellular / animal models, and natural history studies have provided 
insight into the aging process and the increased risk of dementia in individuals with DS. It is 
well known that the brain undergoes accelerated aging changes in DS, but biological 
mechanisms for this have not been fully explored. These studies suggest that increased 
expression of HSA21 genes induces many cellular changes, including dysfunction of 
endosomal and lysosomal systems, composition of neurotrophic signaling, increase in 
amyloid aggregation and cognitive defects, and alterations of microglia and astrocyte 
function [219, 226–232]. Genome-wide association studies (GWAS) have identified 25 
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candidate DS-AD risk alleles. In small DS participant datasets, longitudinal telomere length 
changes correlate with cognitive decline and accelerated epigenetic aging in DS is under 
investigation. Investigators probing the gut microbiome in people with DS have identified 
bacterial species that correlate with Aberrant Behavior Checklist (ABC) scores [233]. In 
addition, novel biomarker methods including neuron-derived exosomes and more sensitive 
plasma-based assays allow early diagnostics and a potential to better evaluate efficacy of 
interventions [234, 235].
Clinical phenotyping, biomarker development and validation in DS, and neuropathological 
diagnostic research have also progressed in recent years, enabling several clinical trials of 
potential AD therapeutics in individuals with DS. In addition, animal and cellular models in 
development have enabled exploration of therapeutic approaches, with early evidence that 
immune approaches may be feasible [236]. Many collaborations and partnerships have been 
established in recent years to accelerate research on DS-AD, including:
• Horizon 21, a multisite study in Europe recruiting a trial-ready cohort [237]
• The Alzheimer’s Biomarker Consortium-Down Syndrome (ABC-DS) – defining 
conversion to dementia based on biomarkers [238]
• Longitudinal Investigation For the Enhancement of Down Syndrome Research 
(LIFE-DSR) – an observational cohort study [239]
• Alzheimer’s Clinical Trials Consortium - Down Syndrome (ACTC-DS) is 
preparing to recruit a trial-ready cohort [240]
• 3-Star study of the candidate vaccine, ACI-24 sponsored by AC Immune is 
nearing completion; AC Immune will also soon launch a Phase 2 trial of β-
amyloid vaccine in adults with DS [241]
20. Alzheimer’s disease and aging research gaps
More research support is needed to better understand the genetics and epigenetics of DS-
AD. The underlying mechanisms that lead to high APP expression in DS-AD pathogenesis 
is not well understood. For example, genetic and epigenetic regulation of APP expression 
remains largely unexplored in people with DS. Epigenetic aging studies have been virtually 
unexplored in DS and could lead to novel genetic pathways that are amenable to 
intervention. Another yet unexplored area is the influence of specific microRNAs in the AD 
pathology. Chr. 21 contains several microRNAs, of which some have been shown to affect 
AD pathology. There is a need to perform sampling at multiple time points to evaluate 
trajectories across the lifespan. To explore the role of additional genetic AD risk factors, it 
will also be valuable to compare GWAS hits in DS-AD to those from late onset AD (LOAD) 
including their association with age of onset, cognitive decline, and variation in risk by sex 
or ethnicity. Other risk factors also need research attention such as sex, race, ethnicity, the 
role of inflammation, the immune system, and potential links to cerebrovascular pathology 
in DS-AD across the lifespan. There is a need to further refine the amyloid/tau/ 
neurodegeneration framework in DS for comparison to LOAD and dominantly inherited AD 
and to identify where and how neuroinflammation and cerebrovascular pathology contribute. 
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The efficacy of treatments and care models in DS-AD are knowledge gaps. The use of 
approved AD drugs in people with DS needs study to determine if these widely used drugs 
are safe and/or appropriate for DS-AD. It is unknown if the therapeutic window of approved 
AD drugs is different for DS-AD as compared with LOAD. In addition, new care models 
need to be developed that enhance the quality of life and longevity in individuals with DS-
AD.
21. Community engagement
Community engagement is a continuum depending upon the level of collaboration between 
researchers and the community yet is essential since members of the DS community can 
give meaningful insight into issues that are important to them across the lifespan. 
Community members should thus be included in all aspects of research studies, starting with 
the design of the study, the determination of inclusion and exclusion criteria, the selection of 
outcome measures, the recruitment of participants, and the development of informed consent 
procedures. As a research study progresses, members of the DS community should continue 
to be included in discussions of the progress of the study, interim results, and 
communication protocols with research participants.
Community engagement research focuses on ensuring that the inclusion of community 
members in studies achieves the goals of improving their understanding of the purpose of 
research, optimizes recruitment for clinical studies, improves the reliability and validity of 
measurement tools, and improves the translation of research into practice. The Community 
Engagement working group recommended the need to communicate the message better so 
that people with DS understand the reason for the research. They also called for the 
development of strategies to increase participation of people with DS in clinical trials and to 
engage individuals with DS in the design of such trials.
22. Community engagement gaps
A recent survey of 256 individuals with DS found that 86% want new treatments and 
interventions, but 64% never participated in research studies. In addition, for those that have 
participated in research studies, direct interviews with individuals with DS and their 
caregivers found a lack of meaningful engagement with them at each step of the research 
process. Increased efforts are needed to better understand the factors that lead to individuals 
with DS being significantly under-represented and oftentimes excluded from research 
studies, including potential discrimination, rigid inclusion and exclusion criteria, low 
prioritization and limited community outreach and awareness. More infrastructure is needed 
for outreach and information sharing and dissemination. In particular, new outreach 
approaches are needed for the older adult community who tend to live outside the family 
unit in independent living, groups homes and long-term care facilities.
23. General research needs
Each workgroup identified research needs for their specific focus area and many of these 
research gaps have been highlighted above. However, the workgroups also identified areas 
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that represent clear DS research needs that cross multiple disciplines. The table below 
summarizes eight areas of overall research need that, if funded, would significantly improve 
the understanding of DS and lead to improvements in treatments and quality of life. The 
eight overall topic areas are clinical and genetic phenotyping, cellular and animal models of 
DS, longitudinal studies, randomized controlled trials in the DS population, centralized 
biorepository, open access centralized DS data, research training for clinicians and scientists, 
and research inclusion. The workgroups also developed a comprehensive list of 




While it is true that the life expectancy for people with DS has increased significantly in 
recent decades thanks to advances in medical care, this review clearly demonstrates that 
many scientific gaps remain that prevent further advances in the discovery of new treatments 
and improvements in quality of life. These research recommendations were developed 
specifically in response to the NIH RFI and it is the hope of the coauthors that the NIH will 
not only include the recommendations submitted and published here in their Research Plan 
on Down Syndrome, but also provide sufficient funding for implementation. The coauthors 
also recognize that, for these recommendations to achieve their desired result, a coordinated 
approach with other funders of research, including other U.S. government agencies, and 
non-government organizations is needed. In addition, it is hoped that this paper will serve as 
a call to action for policymakers and the DS community around a focused and 
comprehensive national Down syndrome research strategy.
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Table 1
Overall Priority Recommendations for DS Research
Recommendations Milestones
Clinical and Genetic Phenotyping
Establish a panel of DS experts to 
define clinical and genetic phenotypes
- Define DS phenotypes for clinical trials from existing data
- Develop clinical guidelines and personalized medicine approaches unique to DS
- Identify changes related to stage of life and aging including inflammation and metabolism
Conduct an “All of US” DS sub-study 
of 5000 participants
- Use GWAS and clinical data to help define DS phenotypes
Expand genetic and epigenetic profiling 
beyond Chr21
- Elucidate complex gene-network effects and incorporate knowledge from non-DS populations
Gather more unbiased -Omics data - Global and tissue specific metabolomics data to help establish metabolic phenotypes and to 
discover new biomarkers of metabolic disease.
- Lipidomics data to better understand the risk of diabetes and obesity in DS
- Comprehensive ‘omics’ in brain samples to define genome, epigenome, metabolome, 
transcriptome and proteome
- Microbiome (i.e. gut, oral) to better understand the potential associations of the microbiome to 
diseases common in DS
Expand the DS Connect portal and 
collect DS to compare with data from:
- the general population
- people with intellectual disabilities but without DS
- siblings of people with DS who do not have DS themselves
- people with autosomal dominant AD
Cellular and animal models of DS
Current understanding of DS 
neurobiology is derived largely from 
mouse studies (Ts65Dn, Tc1) including 
anatomical and behavioral analyses of 
organismal brain development. Develop 
and validate mouse models that better 
translate to characteristics in individuals 
with DS
- Support for new in vivo models that will better represent HSA21 genetic changes are needed.
- Determine the extent of correspondence between findings in models and human biomarkers.
- Perform comparative phenotyping including aging and lifespan of all DS mouse models.
- Comprehensive ‘omics’ including the metabolome in all DS mouse models (including aging 
studies) are needed to better characterize these models.
- Define and compare genetics, mechanisms and significance of dysregulated endosomes, exosomes, 
autophagosome, and proteostasis in all DS mouse models.
- Map pathogenesis pathways in the DS mouse models, testing for the contribution of individual 
dysregulated genes.
- Design new treatment paradigms and pathways for testing in DS mouse models (dose-response/
toxicity studies).
Support new models (including in 
mouse, rat, or non-human best model 
DSprimate) that
- Develop animal models that can reflect the structural changes in human DS brain and other 
differences such as the immune system.
Develop novel cellular models of DS - Support development of human DS cellular models (e.g. induced pluripotent stem cell (iPSC) 
neuronal cultures), exploring variation by both sex and genetic ancestry.
- Develop the use of human iPSC models for more organ systems and pathways affected in DS.
Increase collaboration between bench to 
bedside researchers to share results and 
enhance translational research in DS.
- Ensure that clinical scientists have the tools to implement advances from bench research, and that 
bench discoveries are important to clinical researchers.
- Identify gaps and discrepancies between basic research and clinical observations and address them.
- Facilitate collaborations between neuropathologists and DS clinicians to assess translational 
relevance of model systems and biomarkers to DS neurobiology.
- Explore links between cellular phenotypes/mechanisms in DS mouse models with clinical findings 
including fluid biomarkers.
- Translate insights from mouse models to clinic to inform possible treatments and novel trial 
designs.
Longitudinal Studies
Support studies in the DS population 
over the life course and help to define 
clinical phenotypes to inform future 
research including clinical trials.
- Expand and extend on-going longitudinal studies to keep these important cohorts generating 
valuable data from more people for more years.
- Conduct longitudinal studies across all age groups including adolescents and young adults.
- Facilitate international communication and data sharing of between research studies – e.g. ABC-
DS/Horizon 21.
Within existing and new longitudinal 
cohorts, support efforts to more clearly 
define and chart trajectory of:
- Cognitive function.
- Behavioral assessments.
- Include participant and caregiver reported outcomes.
- Include biomarkers as available (imaging, fluid and genetic)
- Sex effects.
- Contribution of comorbid conditions such as thyroid function, heart disease, obesity, metabolic 
disorders, autoimmune disorders, OSA to health.
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Recommendations Milestones
- Environmental influences such as education, home setting, work, medications, and use of 
supplements.
- Incorporate new technology, data, and/or samples as appropriate. For example, as new low-cost 
genome sequencing technology becomes available, studies could add genomics to existing cohorts.
Establish new DS cohorts with specific 
goals
Develop partial trisomy and mosaic DS cohorts, including bio-samples, iPSC lines and brain banks.
Randomized Controlled Trials (RCT) in the DS Population
Expand support for drug and devise 
RCT’s across the DS lifespan
- Build and sustain trial-ready DS cohorts across the lifespan.
- Assess benefits across the lifespan to improve cognitive outcomes in childhood and delay declines 
in adulthood
- Determine the age when an intervention will have the most benefit for people with DS.
- Support for more drug repurposing trials in DS where target and mechanistic rationales exist.
Support for RCT’s on the efficacy of 
life-style interventions in the DS 
population across the lifespan. Explore 
outcomes of physical fitness, health, 
behavior, cognition, and development.
- Test interventions that effectively increase physical activity and reduce sedentary behavior.
- Develop effective lifestyle interventions that foster healthy behaviors.
- Test interventions that reduce obesity and improve overall health outcomes.
- Test the efficacy of technologies (i.e. animal-assisted therapies, digital, wearable technology) to 
promote healthy behaviors.
Support research to enable RCT’s in 
DS.
- Find an appropriate control population with which to compare DS participants (related to BMI, BP, 
activity levels, intellectual disability, etc.).
- Conduct studies with large enough sample sizes to produce statistical power and significance to 
generalize the results to the larger DS population.
- Explore differences in drug metabolism (pharmacokinetics / pharmacodynamics) and drug safety 
in both children and adults with DS compared with the general population for experimental drug 
candidates and with FDA-approved drugs.
Establish the safety and efficacy of FDA 
approved drugs in both children and 
adults with DS via RCT’s.
- Conduct RTC’s in drugs commonly used to treat mood disorders, cognitive deficits, autoimmune 
disorders, and other manifestations.
- Document side effect, safety and efficacy data including behavioral and cognitive effects of 
approved drugs.
- Improve assessment and management of side effects during treatment. (i.e. pain/nausea during 
cancer therapy).
Expand support for clinical trial 
recruitment.
- Support efforts to inform participants and caregivers of the value of research activities and 
encourage trial participation.
- Build infrastructure to facilitate enrollment in clinical trials with disease-specific or condition-
specific sub-groups.
- Expand expertise in recruiting specific age ranges particularly for adults and underrepresented 
groups.
- Expand DS Connect or establish other approaches to support clinical trial recruitment.
Expand support and training in the 
conduct of DS RCT’s - Provide training to sites that may not have clinical research experience or DS clinical experience.
Develop and disseminate methodology 
for studying cognitive/behavior 
outcome measures in the context of 
large, multi-site trials.
- Develop or employ outcome measures that have demonstrable clinical utility (i.e. predict real-
world changes in behavior, cognition, and/or adaptive skill independence).
- Identify the participants that may be appropriate for a clinical trial given the selected outcome 
measures.
Expand clinical trial data sharing - Harmonize DS clinical protocols with between networks in the US and internationally to enable 
more meaningful data sharing.
Centralized Biorepository
Expand support for centralized (or 
virtual) biorepository of DS samples 
collected across the life span.
- Expand support for brain banks and fluid biobanks from well-characterized participants with 
clinical, behavioral, and functional data and with REDCap accessibility.
- Establish a robust plan for banking of cells, plasma, serum, CSF, and brains either centrally or 
tracked via a virtual repository.
- Produce and store specific cells types such as peripheral blood mononuclear cells (PBMC’s), 
iPSC’s and exosomes (brain derived and peripheral).
- Establish a fair and equitable process for reviewing and approving request for access to samples.
- The collection and storage of the samples should be standardized using established “best 
practices”.
- Integrate biobanking efforts with existing “best practices” for genomic data-sharing, including file 
formats, storage/hosting solutions, and versioning protocols.
- Prioritize (epi)genome-wide profiling over candidate-gene profiling to address diminishing costs of 
throughput while preserving scarce and highly valuable tissue samples.
- Integrate the biorepository data with DS Connect to increase the value of both resources.
Open Access Centralized DS Data
Establish a single network for DS data. - Continue efforts to establish data standards and data sharing in the DS research community.
- Establish a centralized data repository or federated network where researcher can go as a “one-
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Recommendations Milestones
stop-shop” for DS data.
- The centralized data repository mentioned above could include information on access to 
biorepositories and access to well-characterized sample.
- Support long standing DS clinics to digitize their clinical data into an open access, searchable 
format
- Support the creation of curated data sets that included assessment, survey, and transcription DS 
data leading to large data sets that support the use of computational modeling.
Research Training for Clinicians and Scientists
Support training clinical trials and 
clinical neuroscience in DS.
- Provide training for clinicians and researchers in DS who are both established and early in their 
career to attract them to the field.
- Support the development of Master Clinics for Adults with DS (MCADS) that operate on a hub 
and spoke model to provide adults access to expertise across the US, train physicians in DS medical 
care and that enable clinical trial readiness activities.
- Encourage interdisciplinary research collaboration and support cross disciplinary training with a 
focus on DS.
Research Inclusion
Expand the inclusion of individuals 
with DS who have been significantly 
under-represented and oftentimes 
excluded from all sorts of research.
- Develop strategies to increase the participation of people with DS in non-DS focused research.
- Develop strategies to increase participation in research focused on DS-specific priorities of people 
with DS.
- Increase the participation of people with DS in the design of studies for both DS and non-DS 
specific research.
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